Compare Natera Inc. Common Stock (NTRA) vs PPL Corporation Common Stock (PPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs PPL Corporation Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while PPL Corporation Common Stock trades at $35.08 (market cap $26.15B). The key difference: Natera Inc. Common Stock is far larger — about 2.2× PPL Corporation Common Stock's market cap, and PPL Corporation Common Stock pays a 3.28% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and PPL Corporation Common Stock for 5 Days on average.
| NTRA | PPL | |
|---|---|---|
Market Cap | $57.03B | $26.15B |
Volume | 1,131,157 | 5,207,054 |
Sector | Health | Utilities |
52-Week High | $425.64 | $39.81 |
52-Week Low | $179.42 | $31.97 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $56.18B | $46.14B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PPL Corporation trades at $34.63, up 0.84% with a bullish technical outlook supported by moving averages. The utility company shows solid fundamentals with $9.04B revenue, 13.47% net margin, and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $39.45 price target, representing 14% upside potential from current levels. Recent news highlights PPL's $23B infrastructure investment plan and focus on meeting rising electricity demand through strategic capacity expansion.
PPL presents a compelling investment case with strong analyst support, dividend growth potential, and strategic positioning in the growing utility sector. Key risks include execution challenges from the massive capital expenditure program, regulatory hurdles, and competitive pressures. The stock's current valuation at 20.49 P/E appears reasonable given the company's growth trajectory and defensive characteristics in the utility space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About PPL Corporation Common Stock
PPL Corporation is a regulated utility holding company. Through its subsidiaries, it generates, transmits, distributes, and sells electricity and natural gas in Kentucky, Pennsylvania, and Rhode Island.
Read more on PPL →
